392 related articles for article (PubMed ID: 30167846)
1. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
[TBL] [Abstract][Full Text] [Related]
2. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
3. Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.
Gasparian ME; Bychkov ML; Yagolovich AV; Dolgikh DA; Kirpichnikov MP
Biochemistry (Mosc); 2015 Aug; 80(8):1080-91. PubMed ID: 26547077
[TBL] [Abstract][Full Text] [Related]
4. [Antitumor Activity of TRAIL-Mu3 Protein
Yang T; Zhu AJ; Wang JS; Jin Z
Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 May; 51(3):304-311. PubMed ID: 32543134
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.
Yan S; Qu X; Xu C; Zhu Z; Zhang L; Xu L; Song N; Teng Y; Liu Y
J Cancer Res Clin Oncol; 2012 Aug; 138(8):1279-89. PubMed ID: 22447040
[TBL] [Abstract][Full Text] [Related]
6. TRAIL mutant membrane penetrating peptide alike (TMPPA) TRAIL‑Mu3 enhances the antitumor effects of TRAIL in vitro and in vivo.
Zhu H; Yan J; Xu Q; Wei L; Huang X; Chen S; Yi C
Mol Med Rep; 2017 Dec; 16(6):9607-9612. PubMed ID: 29039511
[TBL] [Abstract][Full Text] [Related]
7. Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors.
Phillips DC; Buchanan FG; Cheng D; Solomon LR; Xiao Y; Xue J; Tahir SK; Smith ML; Zhang H; Widomski D; Abraham VC; Xu N; Liu Z; Zhou L; DiGiammarino E; Lu X; Rudra-Ganguly N; Trela B; Morgan-Lappe SE
Cancer Res; 2021 Jun; 81(12):3402-3414. PubMed ID: 33687950
[TBL] [Abstract][Full Text] [Related]
8. A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression.
James MA; Seibel WL; Kupert E; Hu XX; Potharla VY; Anderson MW
Anticancer Drugs; 2015 Jun; 26(5):518-30. PubMed ID: 25646742
[TBL] [Abstract][Full Text] [Related]
9. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
[TBL] [Abstract][Full Text] [Related]
10. TRAIL mutant membrane penetrating peptide alike-MuR6-TR enhances the antitumor effects of TRAIL in pancreatic carcinoma both in vitro and in vivo.
Sun L; Chen C; Zhu A; Huang Y; Zhu H; Yi C
Int J Mol Med; 2017 Jun; 39(6):1468-1476. PubMed ID: 28487979
[TBL] [Abstract][Full Text] [Related]
11. Azithromycin enhances anticancer activity of TRAIL by inhibiting autophagy and up-regulating the protein levels of DR4/5 in colon cancer cells in vitro and in vivo.
Qiao X; Wang X; Shang Y; Li Y; Chen SZ
Cancer Commun (Lond); 2018 Jul; 38(1):43. PubMed ID: 29970185
[TBL] [Abstract][Full Text] [Related]
12. TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor.
Nahacka Z; Svadlenka J; Peterka M; Ksandrova M; Benesova S; Neuzil J; Andera L
Biochim Biophys Acta Mol Cell Res; 2018 Mar; 1865(3):522-531. PubMed ID: 29278689
[TBL] [Abstract][Full Text] [Related]
13. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
[TBL] [Abstract][Full Text] [Related]
14. Naringenin up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer A549 cells.
Jin CY; Park C; Hwang HJ; Kim GY; Choi BT; Kim WJ; Choi YH
Mol Nutr Food Res; 2011 Feb; 55(2):300-9. PubMed ID: 20669244
[TBL] [Abstract][Full Text] [Related]
15. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer.
Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
[TBL] [Abstract][Full Text] [Related]
16. The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand.
Yang SZ; Xu F; Zhou T; Zhao X; McDonald JM; Chen Y
J Biol Chem; 2017 Jun; 292(25):10390-10397. PubMed ID: 28476883
[TBL] [Abstract][Full Text] [Related]
17. Recombinant protein TRAIL-Mu3 enhances the antitumor effects in pancreatic cancer cells by strengthening the apoptotic signaling pathway.
Huang M; Yi C; Huang XZ; Yan J; Wei LJ; Tang WJ; Chen SC; Huang Y
Oncol Lett; 2021 Jun; 21(6):438. PubMed ID: 33868476
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
Kim YH; Jung EM; Lee TJ; Kim SH; Choi YH; Park JW; Park JW; Choi KS; Kwon TK
Free Radic Biol Med; 2008 Mar; 44(6):1055-68. PubMed ID: 18164688
[TBL] [Abstract][Full Text] [Related]
19. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer.
Ozawa F; Friess H; Kleeff J; Xu ZW; Zimmermann A; Sheikh MS; Büchler MW
Cancer Lett; 2001 Feb; 163(1):71-81. PubMed ID: 11163110
[TBL] [Abstract][Full Text] [Related]
20. Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation.
Horinaka M; Yoshida T; Nakata S; Shiraishi T; Tomosugi M; Yoshikawa S; Wakada M; Sakai T
Cancer Sci; 2012 Feb; 103(2):282-7. PubMed ID: 22077238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
